Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.55 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711508 | 1.00 | TDP1 (0.62) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL4740816 | 0.98 | TDP1 (0.65) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL7936987 | 0.97 | TDP1 (0.64) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL13049575 | 0.97 | TDP1 (0.64) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL26490546 | 0.97 | TDP1 (0.64) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL10277136 | 0.97 | TDP1 (0.64) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL15482071 | 0.97 | TDP1 (0.64) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL4904852 | 0.97 | TDP1 (0.64) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL31135784 | 0.97 | TDP1 (0.61) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL31135781 | 0.97 | TDP1 (0.61) | TDP1PKMMEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178580-B1 | BF 844 FOR USE IN THE TREATMENT OF CANCER | USHER III INITIATIVE INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| EP-4450490-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | Prazer Therapeutics Inc. (KR) | 2024-10-23 | — | — | EP | disclosed |
| US-20240279229-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-118382620-A | Novel compounds for degrading target proteins or polypeptides by multiple ubiquitination | 普瑞泽治疗公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023113457-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023113457-A1 | NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION | (주)프레이저테라퓨틱스 | 2023-06-22 | — | — | WO | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-4178580-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | Usher III Initiative, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| EP-3307742-B1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE INC (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | TDP1 1328/4885PKM 2578/4885MEN1 2173/4885 |
| US-20240279229-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | TDP1 1328/4885PKM 2578/4885MEN1 2173/4885 |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | TDP1 2834/4885PKM 1276/4885MEN1 2860/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | TDP1 1010/4885PKM 3882/4885MEN1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.